Captrust Financial Advisors Apellis Pharmaceuticals, Inc. Transaction History
Captrust Financial Advisors
- $46.7 Billion
- Q3 2025
A detailed history of Captrust Financial Advisors transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 21,111 shares of APLS stock, worth $429,186. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,111
Previous 29,532
28.51%
Holding current value
$429,186
Previous $511,000
6.65%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding APLS
# of Institutions
328Shares Held
124MCall Options Held
4.12MPut Options Held
756K-
Avoro Capital Advisors LLC New York, NY12.2MShares$248 Million3.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.99MShares$203 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.64MShares$196 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.29MShares$189 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8MShares$163 Million5.71% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.23B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...